AUSTIN, Texas / Nov 07, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in November.
• | Stephens Annual Investment Conference | |
| Tuesday, Nov. 14 at 12:00 pm ET | 9:00 am PT in Nashville, TN | |
• | Piper Sandler 35th Annual Healthcare Conference | |
| Tuesday, Nov. 28 at 2:30 pm ET | 11:30 am PT in New York, NY |
A live webcast and audio archive of each event may be accessed through the investor relations section of the Natera website at investor.natera.com. Replays of the events will be available shortly following the conferences.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
Last Trade: | US$173.06 |
Daily Change: | 0.97 0.56 |
Daily Volume: | 837,740 |
Market Cap: | US$23.750B |
October 01, 2025 September 29, 2025 August 28, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load